Physician profile
Ronald G Ray
NPI 1104807411
$165,761.93
in general payments reported to CMS, 2019-2025
24 companies · $10K in 2025
The $10K reported for 2025 was more than what 96% of Foot & Ankle Surgery providers received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $42K · 2020: $69.79 · 2021: $19K · 2022: $24K · 2023: $63K · 2024: $7,442 · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $61K · Travel and Lodging: $9,381 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $6,000 · Food and Beverage: $2,461 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,375.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $61,235.75 |
| Travel and Lodging | $9,381.09 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $6,000.00 |
| Food and Beverage | $2,461.42 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,375.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paragon 28, INC. | $144,754.12 | 2019-2025 | Portfolio, Mtp, Apex 3d |
| Synthes Gmbh | $16,070.09 | 2023-2025 | |
| Alafair Biosciences, INC. | $1,438.34 | 2022-2025 | Versawrap |
| Smith+Nephew, INC. | $856.07 | 2021-2025 | Grafix Pl, Stravix Pl |
| Vilex LLC | $585.92 | 2021-2024 | |
| Sioux Surgical INC | $325.63 | 2022-2025 | |
| Kerecis Limited | $296.72 | 2019 | |
| Sanara Medtech INC. | $195.83 | 2022 | |
| Organogenesis INC. | $183.77 | 2019-2020 | |
| Restor3d, INC. | $126.29 | 2024 | |
| Bone Support INC. | $111.96 | 2021 | |
| Zimmer Biomet Holdings, INC. | $96.78 | 2024 | Itst Inst/Nails/Plates/Screws |
| Voom Medical Devices, INC. | $91.00 | 2025 | Revcon |
| Next Science LLC | $89.60 | 2022 | |
| Averitas Pharma INC. | $87.58 | 2023-2025 | Qutenza |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Treace Medical Concepts, INC. | $83.56 | 2025 | |
| Ossio INC | $79.70 | 2021-2023 | |
| Integra Lifesciences Corporation | $70.94 | 2019-2024 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Biopoly LLC | $65.80 | 2024 | |
| Grt US Holding, INC. | $45.69 | 2022 | |
| Embody, INC. | $40.94 | 2021 | |
| International Life Sciences | $26.32 | 2024 | Flexband |
| Solventum Corporation | $21.65 | 2024 | Promogran Prisma, Activ.A.C. |
| Stryker Corporation | $17.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,200,000.24 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Ray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.